Anti-Cholesterol PCSK9 Race: Regeneron, Sanofi Lead Dogs
With a year's worth of progress on the would-be competition targeting cholesterol by way of a new mechanism, Regeneron Pharmaceuticals Inc. and partner Sanofi SA set forth on another Phase III trial this time measuring cardiovascular (CV) outcomes with SAR236553/REGN727.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.